Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells.

Autor:	Riou C; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa cr.riou@uct.ac.za.; Division of Medical Virology, Dept of Pathology, University of Cape Town, Observatory, South Africa., Schäfer G; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.; International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town, Observatory, South Africa.; Division of Medical Biochemistry and Structural Biology, Dept of Integrative Biomedical Sciences, University of Cape Town, Observatory, South Africa., du Bruyn E; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.; Dept of Medicine, University of Cape Town, Observatory, South Africa., Goliath RT; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa., Stek C; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.; Dept of Medicine, University of Cape Town, Observatory, South Africa.; Dept of Infectious Diseases, Imperial College London, London, UK., Mou H; Dept of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA., Hung D; Dept of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA., Wilkinson KA; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.; Dept of Medicine, University of Cape Town, Observatory, South Africa.; The Francis Crick Institute, London, UK., Wilkinson RJ; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.; Dept of Medicine, University of Cape Town, Observatory, South Africa.; Dept of Infectious Diseases, Imperial College London, London, UK.; The Francis Crick Institute, London, UK.
Jazyk:	angličtina
Zdroj:	The European respiratory journal [Eur Respir J] 2022 Jan 13; Vol. 59 (1). Date of Electronic Publication: 2022 Jan 13 (Print Publication: 2022).
DOI:	10.1183/13993003.00285-2021
Abstrakt:	Background: Rapid tests to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell responses are urgently needed to decipher protective immunity and aid monitoring vaccine-induced immunity. Methods: Using a rapid whole blood assay requiring a minimal amount of blood, we measured qualitatively and quantitatively SARS-CoV-2-specific CD4 T-cell responses in 31 healthcare workers using flow cytometry. Results: 100% of COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4 T-cell response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no COVID-19-associated symptoms or who tested PCR-negative. Phenotypic assessment indicated that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early differentiated memory phenotype with limited capacity to produce interferon (IFN)-γ. Conversely, in participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late differentiated cells, coexpressing IFN-γ and tumour necrosis factor-α and also Granzyme B. Conclusions: This proof-of-concept study presents a scalable alternative to peripheral blood mononuclear cell-based assays to enumerate and phenotype SARS-CoV-2-responding T-cells, thus representing a practical tool to monitor adaptive immunity due to natural infection or vaccine trials. Competing Interests: Conflict of interest: C. Riou has nothing to disclose. Conflict of interest: G. Schäfer has nothing to disclose. Conflict of interest: E. du Bruyn has nothing to disclose. Conflict of interest: R.T. Goliath has nothing to disclose. Conflict of interest: C. Stek has nothing to disclose. Conflict of interest: H. Mou has nothing to disclose. Conflict of interest: D. Hung has nothing to disclose. Conflict of interest: K.A. Wilkinson has nothing to disclose. Conflict of interest: R.J. Wilkinson reports grants from Wellcome, Cancer Research UK, UK Research and Innovation, and the European and Developing Countries Clinical Trials Partnership, during the conduct of the study. (Copyright ©The authors 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu